3. Quick and accurate sequencing
Utilizing our accumulated technology and algorithms, the COPAS and MALDI-TOF/MS analysis devices facilitate swift and precise sequencing of substantial candidate
materials, setting us apart from competitors in terms of efficiency and accuracy.
2. High selectivity and excellent binding
By refining the Bead-Peptide coupling during the peptide library synthesis phase and incorporating zwitterionic dye, our technology enables precise peptide screening
for target proteins, surpassing conventional methodologies in specificity and affinity sequencing.
1. High blood stability
By incorporating unnatural amino acids during the initial library construction stage, we can synthesize peptides that exhibit exceptional stability in the bloodstream.
Our innovative discovery platform, CUS™, facilitates the identification of peptides with remarkable stability and selectivity through a three-differentiated approach:
(1) Crafting a high-purity library using an optimized process, (2) Employing a novel screening procedure that minimizes background interactions, and
(3) Achieving direct sequencing utilizing our proprietary analyzing algorithm.
Technology
Peptide Discovery Platform CUS™
Points of differentiation (CUS™ Platform)
Publication
Directing GDNF-mediated neuronal signaling with proactively programmable cell-surface saccharide-free glycosaminoglycan mimetics
Chemical Communication
2019
Facile saccharide-free mimetics that recapitulate key features of glycosaminoglycan sulfation Patterns
Chemical Science
2018
combinatorial Bead-Based Peptide Libraries Improved For Rapid and Robust Screenings
Current Topics in Medicinal Chemistry
2017
An Efficient Strategy to Enhance Binding Affinity and Specificity of a Known Isozyme Inhibitor
Organic & Biomolecular Chemistry
2016
Self-Assembling Peptide Nanofibrous Hydrogel as a Versatile Drug Delivery Platform
Current Pharmaceutical Design
2015
Enzymatic conjugation of a bioactive peptide into an injectable hyaluronic acid–tyramine hydrogel system to promote the formation of functional vasculature
Acta Biomaterialia
2014
In Situ Click Chemistry: from Small Molecular Discovery to Synthetic Antibodies
Integrative Biology
2013
Process Automation toward Ultra-High Throughput Screening of Combinatorial One-Bead-One-Compound(OBOC) Peptide Libraries
Journal of Laboratory Automation
2012
Iterative in Situ Click Chemistry Assembles a Branched Capture Agent and Allosteric Inhibitor for AKT1
Journal of The American Chemistry Society
2011
Accurate MALDI-TOF/TOF Sequencing of One-Bead-One-Compound Peptide Libraries with Application to the Identification of Multiligand Protein Affinity Agents Using In Situ Click Chemistry Screening
Analytical Chemistry
2010
Subject
Journal
Year
Download
Partners
C-Biomex is seeking strategies to diversify new drug development for developing innovative treatments through continuous cooperative research with domestic and foreign companies and professional research institutes.
R&D/Industry: Trioar, Eflask, Portrai, Pohang Pohang Techno Park
R&D/Academy: Seoul National University, JHU, Korea Institute of radiological & medical sciences
Technology
Theragnostic represents a dual-purpose strategy involving both cancer diagnosis and treatment, utilizing radiotracers. Radiotracers are composed of radiation and chemicals that specifically attach to a particular target within the body. Achieving this entails accurate targeting of radioactive isotopes to the tumor while ensuring rapid elimination to minimize any potential toxicity.
Discovery & Development of Radio Ligand Theragnostic
1. Differential advantages of C-biomex radio ligand theranostics: excellent PK Profile
2. Strong targeting for cancer and minimizing toxicity through fast clearance (Hit Hard Leave Fast)
Points of differentiation (CUS™ Platform)
